When a Disease Has No Name
A toddler named KJ Muldoon arrived at Great Ormond Street Hospital in London with a metabolic crisis. His body was accumulating ammonia to toxic levels, poisoning his developing brain. The usual suspects had been ruled out. Standard genetic panels came back inconclusive. The condition was so rare that when doctors finally identified it — a deficiency in the CPS1 enzyme, a protein critical for nitrogen metabolism — they found fewer than a handful of documented cases worldwide. For all practical purposes, KJ had a disease that medicine had never learned to treat because so few people had ever had it.
What happened next is genuinely new in medicine. Rather than searching for an existing drug that might help, or hoping that a therapy designed for a slightly different condition could be adapted, doctors and researchers did something more audacious. They designed a therapeutic specifically for KJ, from scratch, in under six months. They used base editing, a molecular precision tool that can correct individual mutations in DNA with minimal collateral damage. By the time KJ received his infusion, the therapy had been crafted for one patient, like a bespoke suit made for the only person who needs it.
Base Editing Changes the Calculus of What’s Treatable
To understand why this matters, you need to grasp what makes base editing different from the CRISPR systems most people have heard about. Traditional CRISPR-Cas9 works by cutting both strands of DNA, then letting the cell’s repair machinery stitch things back together. It works, but it’s blunt. The cell’s repair enzymes sometimes make mistakes. Off-target edits can happen. Unwanted insertions or deletions can occur at the cut site. The process reduces your precision ceiling.
Base editing, pioneered by David Liu’s lab at the Broad Institute, sidesteps that problem entirely. Instead of making cuts, it chemically converts one DNA letter into another. An adenine becomes a guanine. A cytosine becomes a thymine. No breaks. No waiting for repair machinery to reassemble things. Just a targeted chemical transformation that leaves the DNA backbone intact. This matters enormously when you’re working with rare diseases, where every safety margin counts and where you may never get to treat a second patient the same way.
The elegance of the approach becomes obvious when you look at the data. In KJ’s case, NEJM — Personalized Base Editing for CPS1 Deficiency reports that a single infusion brought his blood ammonia levels to near-normal ranges. Six months later, no serious adverse events. The therapy worked precisely as designed because it was designed precisely for him. Broad Institute Base Editing Research has spent years optimizing this technology, but what happened in London was the first time it was deployed in a true bespoke fashion — one therapy, one patient, one disease with no name.
The Undiagnosed Diseases Program Is Quietly Cataloging Your Future Patients
For decades, a patient with a mystery illness faced a grinding odyssey. Specialists in different fields. Conflicting opinions. Genetic tests that returned nothing useful. Years could pass before a diagnosis emerged, if one ever did. The NIH’s Undiagnosed Diseases Program has changed this significantly. Since 2023 alone, they have identified over 1,000 patients with conditions so rare that fewer than 10 people globally have been diagnosed with them. Some affect only a handful of individuals on earth. These are the patients who have been falling through every crack in medicine’s infrastructure because there was no economic incentive to understand their conditions, let alone treat them.
Here is what changes when base editing becomes accessible. Each of these 1,000 patients is a potential candidate for a personalized therapy. Not a drug designed for 100,000 people that might happen to help them. Not a therapy aimed at the most common genetic variant of their condition. An intervention designed for their specific mutation, their specific genetic architecture, their specific illness. The institutional machinery is finally catching up to the reality of human genetic diversity.
And this is where things get interesting. These discoveries are not happening in isolation. Great Ormond Street and the Broad Institute worked in concert. Genome sequencing teams fed data to structural biologists who worked with molecular engineers. Regulatory pathways designed for population-scale therapies had to be reimagined for n-equals-1 medicine. The NIH’s cataloging effort provided the patient population that made sense of the entire enterprise. It required coordination across institutional silos that do not naturally coordinate.
The Economics Are Brutal Right Now — But the Trajectory Is Clear
Let’s be direct about the constraint. Developing a single personalized base-editing therapy currently costs between $500,000 and $2 million. That is not a sustainable model for rare disease treatment at any meaningful scale. If you have only 500 patients worldwide with your condition, and each therapy costs $1.5 million to develop, you’re looking at billions in total cost for a population that cannot possibly sustain that economically. The math does not work.
But researchers are not naive about this. The conversation is already shifting toward modular delivery platforms and manufacturing processes that separate the expensive initial design phase from the delivery engineering. If you can standardize the way you package base-editing machinery and deliver it to the right cells, you can reuse that infrastructure across multiple rare diseases. You test it thoroughly once with patient A, then deploy it again for patients B, C, and D. The fixed costs get spread across the population. Conservative estimates suggest that economies of scale could reduce per-patient costs by 90% within a decade as the field matures.
The real constraint right now is not the science or the manufacturing. It is regulatory clarity and reimbursement frameworks. How do you price a therapy that only one patient will ever need? What does clinical evidence look like when you cannot run trials? How do you make sure a therapy developed for one person gets covered by insurance? These are not scientific questions. They are policy questions, and they are being wrestled with simultaneously by researchers, regulators, patient advocates, and payers who are all discovering that the old playbooks do not apply.
We Are Watching the Transition Happen in Real Time
KJ Muldoon’s case is not a miracle in the sense of defying biology. It is a miracle in the sense of institutional coordination finally catching up to technological capability. For years, base editing was a laboratory achievement. Beautiful to watch. Impeccable in its design. But practically locked away because there was no pathway to get it to the patient who needed it. Now there is. A diagnosis network identifies rare patients. Base-editing technology provides a tool that can be customized rapidly. Regulatory structures are beginning to accommodate personalized approaches. Manufacturing at scale is becoming feasible.
The field is watching itself transform. Researchers who spent their careers assuming they would develop therapies for thousands of people are now designing for one. Regulatory bodies are learning to evaluate evidence when traditional clinical trials are impossible. Hospitals are building the infrastructure to turn genetic information into personalized medicine within months rather than years. This is how paradigm shifts in medicine actually happen, not through revelation, but through the accumulated force of multiple institutions adapting to new realities simultaneously.
What questions are you sitting with as you think about this shift? Are there rare diseases in your family or community where personalized therapies might apply? The conversation about bespoke medicine is just beginning, and the institutional boundaries that will shape it are still being drawn. This is the moment when input from patients, clinicians, and thoughtful observers actually changes how the field develops.